Aerie Pharma (AERI) Reports In-Line Q1 EPS

Aerie Pharma (NASDAQ: AERI) reported Q1 EPS of ($0.66), in-line with the analyst estimate of ($0.66). Revenue for the quarter came in at $29.8 million versus the consensus estimate of $29.76 million.

GUIDANCE:

Aerie Pharma sees FY2022 revenue of $130-140 million.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c
• DA Davidson Reiterates Buy Rating on Boost Run (BRUN)